Acrivon Therapeutics appointed Adam Levy as Chief Financial Officer effective April 1, 2025, with a salary of $490,000 and an annual performance bonus of 40%, while Rasmus Holm-Jorgensen stepped down from the position on April 1, 2025, for personal reasons.